Article Archive: Damien Conover, CFA

Title Collection Author Date
Healthcare: Stock Selection Increasingly Important Quarter-End Insights Damien Conover, CFA 06/30/16
Recent Drug Launches Buoy Bayer's Growth Stock Strategist Damien Conover, CFA 04/27/16
Steady Growth at J&J Reinforces Wide Moat, But Shares Overpriced Commentary Damien Conover, CFA 04/19/16
Allergan Still Undervalued as Likelihood of Pfizer Deal Fades Commentary Damien Conover, CFA 04/05/16
Healthcare: Drug Reform Worries Are Overblown Stock Strategist Damien Conover, CFA 03/29/16
Healthcare Slump Is a Buying Opportunity US Videos Damien Conover, CFA 02/17/16
Pfizer's Pipeline Productivity Is Improving Stock Strategist Damien Conover, CFA 02/05/16
Pfizer Looks Undervalued Commentary Damien Conover, CFA 02/02/16
Steady Growth Supports J&J’s Wide Moat Commentary Damien Conover, CFA 01/26/16
Healthcare: Even After Uptick, Some Great Values Remain Quarter-End Insights Damien Conover, CFA 12/30/15
3 Underappreciated Pharma Stocks US Videos Damien Conover, CFA 11/28/15
Allergan Buy Strengthens Undervalued Pfizer's Moat Commentary Damien Conover, CFA 11/23/15
Pfizer's Fair Value Gets a Booster Commentary Damien Conover, CFA 10/27/15
Merck Looks Undervalued Commentary Damien Conover, CFA 10/27/15
Lilly's Moat Still Intact After Halting Heart Drug Study Commentary Damien Conover, CFA 10/12/15
Health Care: Recent Pullback Opens Door to More Compelling Valuations Quarter-End Insights Damien Conover, CFA 09/30/15
Merck's New Drugs Offset Patent Losses Stock Strategist Damien Conover, CFA 09/25/15
2 High-Quality Health-Care Bargains US Videos Damien Conover, CFA 07/31/15
J&J’s Drug Pipeline Not Strong Enough to Accelerate Growth Commentary Damien Conover, CFA 07/14/15
Health Care: A Few Stocks Still Offer Upside Quarter-End Insights Damien Conover, CFA 07/01/15
This Pharma Firm Passes the Test Stock Strategist Damien Conover, CFA 04/29/15
Market Undervalues Merck’s Pipeline Commentary Damien Conover, CFA 04/28/15
Caution: Slowing Growth Ahead for J&J Commentary Damien Conover, CFA 04/14/15
Health Care: 3 Picks in a More Expensive Sector Quarter-End Insights Damien Conover, CFA 04/01/15
Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price Commentary Damien Conover, CFA 02/05/15
Pfizer May Go Shopping for Growth Commentary Damien Conover, CFA 01/27/15
J&J Faces Headwinds in 2015 Commentary Damien Conover, CFA 01/20/15
Health Care: A Strong Run, but Some Stocks Still Look Undervalued Quarter-End Insights Damien Conover, CFA 12/31/14
Sanofi Shakes Off Patent Losses Stock Strategist Damien Conover, CFA 11/24/14
Led by Drug Sales, J&J Posts Solid Third Quarter Commentary Damien Conover, CFA 10/14/14
Health Care: Some Healthy Bargains Still Remain Quarter-End Insights Damien Conover, CFA 10/01/14
Blockbusters Differentiate Novartis Stock Strategist Damien Conover, CFA 09/05/14
J&J's Strong 2Q Led by Pharmaceuticals Commentary Damien Conover, CFA 07/15/14
Stock-Picking Increasingly Critical in Health Care Quarter-End Insights Damien Conover, CFA 06/28/14
Merck Pays a High Price for Idenix Market Update Damien Conover, CFA 06/09/14
High-Priced Sale of Consumer Business Strengthens This Big Pharma Firm's Moat Stock Strategist Damien Conover, CFA 05/07/14
Pfizer-Astra Deal Will Get Done US Videos Damien Conover, CFA 04/28/14
Johnson & Johnson's Pharma Group Leading the Way US Videos Damien Conover, CFA 04/15/14
The Sector Is Fairly Valued, but These Stocks Are Not US Videos Damien Conover, CFA 04/10/14
Makings of a Wide Moat in Diabetes Care Quarter-End Insights Damien Conover, CFA 03/28/14
AbbVie's Outlook Highly Dependent on Well-Positioned Humira Stock Strategist Damien Conover, CFA 12/14/12
Scale and Patent Protection Integral Parts of Lilly's Moat US Videos Damien Conover, CFA 12/03/12
Our Strong Long-Term Outlook for J&J Intact Market Update Damien Conover, CFA 10/16/12
Large Opportunity for Big Pharma Stock Strategist Industry Reports Damien Conover, CFA 08/06/12
Pfizer Still Looks Undervalued Market Update Damien Conover, CFA 07/31/12
J&J's Long-Term Outlook Remains Favorable Market Update Damien Conover, CFA 07/17/12
Sanofi Posts Slightly Disappointing 4Q Market Update Damien Conover, CFA 02/08/12
Glaxo Turning the Corner to Steady Long-Term Growth Market Update Damien Conover, CFA 02/07/12
Pfizer Posts In-Line 4Q as Generic Lipitor Weighs Market Update Damien Conover, CFA 01/31/12
Abbott Breakup Will Create Two Moaty Companies Stock Strategist Industry Reports Damien Conover, CFA 11/25/11